Academic literature on the topic 'Syndrome néphrotique – Aspect génétique'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Syndrome néphrotique – Aspect génétique.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Syndrome néphrotique – Aspect génétique":
Boyer, O., E. Machuca, E. Esquivel, and C. Antignac. "Notions récentes sur la génétique du syndrome néphrotique cortico-résistant." Archives de Pédiatrie 16, no. 6 (June 2009): 796–98. http://dx.doi.org/10.1016/s0929-693x(09)74157-0.
Servais, A., O. Gribouval, O. Boyer, A. Hummel, J. Dantal, F. Martinez, R. Sberro-Soussan, D. Chauveau, M. Delahousse, and C. Antignac. "Syndrome néphrotique corticorésistant de l’adulte : doit-on chercher une cause génétique ?" Néphrologie & Thérapeutique 14, no. 5 (September 2018): 342. http://dx.doi.org/10.1016/j.nephro.2018.07.208.
El Ansari, Nawal. "Le syndrome de kallmann de morsier aspect génétique." Andrologie 18, no. 2 (June 2008): 127–30. http://dx.doi.org/10.1007/bf03040390.
Karras, A. "Atteinte rénale du syndrome d’activation macrophagique." Médecine Intensive Réanimation 27, no. 4 (June 19, 2018): 300–308. http://dx.doi.org/10.3166/rea-2018-0041.
Dissertations / Theses on the topic "Syndrome néphrotique – Aspect génétique":
Almeida, Gonçalves Sara de. "Identification of new genes involved in hereditary steroid-resistant nephrotic syndrome using next generation sequencing and in vivo functional characterization in drosophila melanogaster." Thesis, Sorbonne Paris Cité, 2017. http://www.theses.fr/2017USPCB030/document.
Nephrotic syndrome (NS) is a kidney disease characterized by disruption of the glomerular filtration barrier and the massive loss of proteins into the urine. Although in the majority of cases treatment with steroids leads to remission of the disease, in 15-20% of cases the disease is not responsive to this therapy and is classified as steroid-resistant nephrotic syndrome (SRNS). SRNS is a clinical condition with high morbidity leading to progressive renal failure as well as multiple metabolic and cardiovascular complications. Extensive research over the last 20 years has identified more than 40 SRNS causing genes that are crucial for function of the podocyte, a highly specialized kidney epithelial cell. However, the mutated gene is still unknown in about half of the familial cases. We have used exome sequencing to identify new genes mutated in SRNS. In order to prove the pathogenicity of the identified mutations we used the Drosophila model, assessing defects of fly viability and the structure and function of nephrocytes, podocyte like-cells. My thesis work consists of two projects. Firstly, we identified biallelic mutations in a new candidate gene, SGPL1, encoding the sphingosine 1- phosphate lyase, in individuals presenting SRNS with facultative adrenal insufficiency, ichthyosis, neurological defects and immunodeficiency. SGPL1 is the main catabolic enzyme of sphingolipids, irreversibly degrading sphingosine 1-phosphate into phosphoethanolamine and hexadecenal. In flies, these mutations were shown to decrease viability, induce nephrocyte defects and lead to the accumulation of sphingoid bases due to the loss of SGPL1 catabolic activity. Together, these results indicate that the identified SGPL1 mutations are pathogenic and cause a new syndromic form of SRNS. Moreover, in a second project, we defined the contribution of homozygous mutations found in two different genes, ADD3 and KAT2B, to a complex phenotype found in affected individuals from one consanguineous family. These individuals presented with neurological defects, cataracts, mild skeletal defects, cardiomyopathy and SRNS. ADD3 encodes adduciny, an F-actin capping protein that also links the actin cytoskeleton to the spectrin based membrane skeleton, while KAT2B encodes the lysine acetyltransferase 2B, mainly known for acetylation of histones and modulation of transcriptional programs. We found additional nonrelated patients carrying only biallelic ADD3 mutations that presented a partially overlapping syndrome but with no cardiac or renal manifestations. In the Drosophila model we found that both ADD3 and KAT2B mutations impaired fly viability and that the ADD3 mutation also impaired fly motor function. However, only the KAT2B mutation induced functional defects in Drosophila heart and nephrocytes. Altogether, these results suggest that ADD3 mutations are responsible for a neurological phenotype with facultative cataracts and skeletal defects while the KAT2B mutation induces heart and kidney defects. These results highlight the Drosophila as a good in vivo model to test the pathogenicity of the mutations found in SRNS candidate genes
Grootenboer, Sabine. "Nouveau syndrome pléi͏̈otropique : stomatocytose +/-, oedèmes +/-, pseudohyperkaliémie." Paris 11, 2001. http://www.theses.fr/2001PA114811.
Vigé, Alexandre. "Epigénomique nutritionnelle du syndrome métabolique." Paris 5, 2007. http://www.theses.fr/2007PA05P602.
Epigenetic changes associated with DNA methylation and histone modifications leading to chromatin remodeling and regulation of gene expression underlie the developmental programming of obesity, type 2 diabetes, cardiovascular diseases and metabolic syndrome. This review focuses on converging data supporting the hypothesis that, in addition to "thrifty genotype" inheritance, individuals with obesity, type 2 diabetes, and metabolic syndrome (MetS) with an increased risk of cardiovascular diseases have suffered improper "epigenetic programming" during their fetal/postnatal development due to maternal inadequate nutrition and metabolic disturbances and also during their lifetime, that could even be transmitted to the next generation(s). We highlight the susceptibility of epigenetic mechanisms controlling gene expression to environmental influences due to their inherent malleability, emphasizing the participation of transposable elements and the potential role of imprinted genes during critical time windows in epigenetic programming, from the very beginning of development, throughout life. Increasing our understanding on epigenetic patterns significance and their role in development, evolution and adaptation and on small molecules (nutrients, drugs) that reverse epigenetic (in)activation should provide us with the means to "unlock" silenced (enhanced) genes, and to "convert" the obsolete human thrifty genotype into a "squandering" phenotype
Huang, Hai. "Biophysical Characterization of Three SCN5A Mutations Linked to Long QT Syndrome Type 3, Sudden Infant Death Syndrome, and Atrial Fibrillation." Thesis, Université Laval, 2010. http://www.theses.ulaval.ca/2010/27250/27250.pdf.
Turcot, Valérie. "Génétique et épigénétique du syndrome métabolique." Thesis, Université Laval, 2012. http://www.theses.ulaval.ca/2012/29169/29169.pdf.
Huang, Hai. "Biophysical Characterisation of Two Mutations Causing Long QT Syndrome and Brugada Syndrome." Thesis, Université Laval, 2006. http://www.theses.ulaval.ca/2006/23724/23724.pdf.
Bossé, Yohan. "Genetic Susceptibility to the Metabolic Syndrome." Thesis, Université Laval, 2004. http://www.theses.ulaval.ca/2004/22151/22151.pdf.
The metabolic syndrome is a cluster of interrelated cardiovascular risk factors co-occurring in the same individual. People with this syndrome are at increased risk for developing diabetes mellitus and cardiovascular diseases. Accordingly, it is important to elucidate the genetic aetiology governing this trait in order to better comprehend its pathogenesis. In the present thesis, heritability and complex segregation analyses as well as candidate gene and genome-wide scan approaches have been applied to shed some lights on the genetic architecture of the metabolic syndrome and its individual components. A total of three candidate genes have been investigated including peroxisome proliferator-activated receptor (PPAR) α and PPARγ as well as phospholipid transfer protein (PLTP). It has been shown that polymorphisms in both PPARα and PLTP genes are significantly associated with several indices of adiposity. In addition, significant gene-gene interactions have been observed between PPARα and PPARγ on glucose/insulin parameters. It has also been shown that the HDL2-cholesterol response to gemfibrozil therapy is modulated by the PPARα L162V polymorphism. Genome-wide linkage scans have been performed on lipid and lipoprotein concentrations. Many chromosome regions harbouring lipoprotein/lipid genes have been identified including 1q43, 11q13 q24, 15q26.1, and 19q13.32 for LDL-cholesterol, 12q14.1 for HDL-cholesterol, 2p14, 11p13, and 11q24.1 for triglycerides, 18q21.32 for LDL-apolipoprotein (apo) B, and 3p25.2 for apoAI. The genetic contribution of the variation in LDL peak particle diameter (LDL-PPD) has been also investigated. Overall, the results indicate: 1) that LDL-PPD strongly aggregates within families with heritability estimate above 50%; 2) the existence of a major gene effect affecting the phenotype; and 3) the presence of a major quantitative trait locus located on chromosome 17q. The apo H gene, a positional candidate gene, was then significantly associated with LDL-PPD, suggesting that this gene is responsible for the linkage signal observed on 17q. Finally, factor analyses have been used to construct a quantitative metabolic syndrome variable and a genome-wide linkage scan has been conducted to identify the genomic regions underlying this trait. A major quantitative trait locus has been observed on chromosome 15q suggesting a gene within this region contributing to the clustering of the metabolic syndrome-related phenotypes. Many of these findings must go through independent replication, while others produced new leads that deserve follow-up.
Inscrit au Tableau d'honneur de la Faculté des études supérieures
Murati, Anne. "Les protéines tyrosine kinases dans les syndromes myéloprolifératifs." Aix-Marseille 2, 2005. http://www.theses.fr/2005AIX20686.
Dury, Alain. "Étude de la compartimentalisation de sous-populations de la Fragile X Mental Retardation Protein au sein de la cellule." Doctoral thesis, Université Laval, 2017. http://hdl.handle.net/20.500.11794/27704.
Fragile X syndrome, a monogenic disease linked to the chromosome X, is the first cause of inherited mental retardation. The syndrome affects about one out of 4000 man, and one out of 6000 woman. Fragile X is caused by the inactivation of the Fragile X Mental retardation (FMR1) gene, leading to the absence of its product, the Fragile X Mental Retardation Protein (FMRP). The absence of FMRP, an RNA binding protein, is believed to cause translation dysregulation and defects in mRNA transport essential for local protein synthesis and for synaptic development and maturation. It is accepted that FMRP possesses a nuclear localisation signal (NLS), and a nuclear export signal (NES), allowing the protein to enter the nucleus, and possibly to exit from it as well. However, available antibodies do not allow to study the nuclear localisation of FMRP. Thanks to a new generation of monospecific antibodies developed in our laboratory, we were able to study the cytoplasmic and the nuclear distribution of FMRP. I will therefore shortly develop the fate of cytoplasmic FMRP (cFMRP) in neurons, and I will characterise the nuclear FMRP (nFMRP) that has been sought after for many years. nFMRP consists in particular nuclear FMRP isoforms that localize to Cajal bodies, structures described more than a century ago by the famous neuroscientist Santiago Ramon y Cajal. Data presented here also raise doubts on the nucleocytoplasmic traficking model, which relies on very few evidence. The discovery of nFMRP could have great implication in the Fragile X domain, opening a whole new field of investigation on the role of FMRP in the cell nucleus, and therefore on the consequences of its absence in patients.
Gillion-Boyer, Olivia. "Rôles de PLCE1 et INF2 dans la physiopathologie des podocytopathies héréditaires." Paris 5, 2011. http://www.theses.fr/2011PA05T044.
During the last decade, the identification of several podocyte genes in hereditary forms of podocytopathies has allowed to refine the glomerular filtration barrier structure and function. We conducted a mutational analysis on a worldwide cohort of 139 patients with nephrotic syndrome and identified 9 novel mutations of the PLCE1 gene encoding the phospholipase Cε1. Surprisingly in an autosomal recessive disease, we observed an incomplete penetrance in 3 pedigrees suggestive of oligogenic inheritance or genetic and/or environnemental modifiers, although the screening of 19 candidate genes failed to identify a causative variant. We confirmed the major role of INF2 encoding a diaphanous-related formin in autosomal dominant podocytopathies. We showed that most INF2 mutations are located in the N-terminal domain of the protein which is involved in its autoinhibition through the binding to its C-terminus, and also interacts with another podocyte and cytoskeletal component IQGAP1. Since INF2 interacts with MAL (Myelin And Lymphocyte protein) and the Rho GTPase Cdc42, essential players of the peripheral myelination process, we hypothesized that INF2 mutations could be involved in the intriguing association of a podocytopathy with the Charcot Marie Tooth peripheral neuropathy. We screened a cohort of 16 families with this neurorenal phenotype and identified mutations in 75% of them. We showed that INF2 is expressed in Schwann cells, where it colocalizes and interacts with MAL, and that mutations in INF2 alter INF2 interaction with Cdc42. This suggests that INF2 mutations could disturb the INF2-MAL-Cdc42 pathway and its role in myelin formation and maintenance
Books on the topic "Syndrome néphrotique – Aspect génétique":
National Down Syndrome Society Conference on Down Syndrome and Alzheimer Disease (1992 New York, N.Y.). Down syndrome and Alzheimer disease: Proceedings of the National Down Syndrome Society Conference on Down Syndrome and Alzheimer Disease, held in New York, January 16 and 17, 1992. Edited by Epstein Charles J, Nadel Lynn, and National Down Syndrome Society (U.S.). New York: Wiley-Liss, 1992.
Symposium on Molecular Genetics of Chromosome 21 and Down Syndrome (1989 New York, N.Y.). Molecular genetics of chromosome 21 and Down syndrome: Proceedings of the Sixth Annual National Down Syndrome Society Symposium, held in New York, NY, December 7-8, 1989. Edited by Patterson David 1944- and Epstein Charles J. New York: Wiley-Liss, 1990.